Showing results (261-270 of 365) with videos related to
Sort By:
Pageof 37
Journal of Palliative Medicine|September 1, 2025
A Longitudinal, Palliative Care Educational Pilot in Hematology-Oncology Fellowship TrainingJessica R Bauman, Madeline Albert, Marcin Chwistek, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 7, 2004
Randomized phase II trial of sequential chemotherapy in advanced non-small cell lung cancer (SWOG 9806): carboplatin/gemcitabine followed by paclitaxel or cisplatin/vinorelbine followed by docetaxelMartin J Edelman, Joseph I Clark, Kari Chansky, et al.Molecular and Cellular Pharmacology|August 16, 2014
Stereotactic Ablative Radiotherapy (SABR): Impact on the Immune System and Potential for Future Therapeutic ModulationAdam S Reese, Steven J Feigenberg, Azmat Husain, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303)Antonius A Miller, Xiaofei F Wang, Lin Gu, et al.Journal of Geriatric Oncology|June 25, 2013
A novel approach to improve health status measurement in observational claims-based studies of cancer treatment and outcomesAmy J Davidoff, Ilene H Zuckerman, Naimish Pandya, et al.Drug and Alcohol Dependence|October 4, 2020
All-cause mortality among males living with and without HIV initiating long-term opioid therapy, and its association with opioid dose, opioid interruption and other factorsK S Gordon, A Manhapra, S Crystal, et al.Neuron|October 27, 2021
Repeated hippocampal seizures lead to brain-wide reorganization of circuits and seizure propagation pathwaysManKin Choy, Ehsan Dadgar-Kiani, Greg O Cron, et al.Clinical Lung Cancer|December 5, 2003
Unfavorable therapeutic index of cisplatin/gemcitabine/vinorelbine in advanced non-small-cell lung cancerPaul J Hesketh, Christopher J Nauman, Ann M Hesketh, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 25, 2009
Pemetrexed plus cetuximab in patients with recurrent non-small cell lung cancer (NSCLC): a phase I/II study from the Hoosier Oncology GroupShadia Jalal, David Waterhouse, Martin J Edelman, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 19, 2013
Obatoclax mesylate, a pan-bcl-2 inhibitor, in combination with docetaxel in a phase 1/2 trial in relapsed non-small-cell lung cancerAlberto Chiappori, Charles Williams, Donald W Northfelt, et al.Pageof 37